<DOC>
	<DOCNO>NCT01741493</DOCNO>
	<brief_summary>This phase 1 , randomize , double-blind , placebo-controlled , multiple ascend dose study healthy volunteer , multiple dose study patient rheumatoid arthritis multiple dose study healthy volunteer .</brief_summary>
	<brief_title>A Study Healthy Adults Adult Subjects With Rheumatoid Arthritis Evaluate Safety , Tolerability Pharmacokinetics After Multiple Doses ABT-494</brief_title>
	<detailed_description>To assess safety , tolerability pharmacokinetics ABT-494 healthy volunteer patient rheumatoid arthritis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy Volunteers : Male female subject 18 55 year age , inclusive . Subject judge good general health . Rheumatoid Arthritis Patients : Male female patient 18 75 year age , inclusive . Subject diagnosis rheumatoid arthritis least six month . Subject methotrexate therapy least three month stable dose least four week . History evidence active latent tuberculosis . History significant allergic reaction drug . Use know strong CYP3A CYP2D6 inhibitor CYP3A inducer within 21 day within 5 halflives respective medication , whichever longer . Current expect need oral intake least 10 mg prednisone per day equivalent corticosteroid therapy . History acute inflammatory joint disease different origin rheumatoid arthritis ( rheumatoid arthritis patient ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Tofacitinib</keyword>
</DOC>